The search found 4069 results.
Imprivata achieves record revenues of $25.3 million, a 41% increase over the comparable period of 2013, and increases annual revenue guidance.
Make a well-informed decision about which two-factor authentication modalities to introduce to your EPCS process: keep prescriber satisfaction in mind
Learn how to successfully deploy a new, secure communications platform at your healthcare facility: secure your success by planning proactively
A seasoned physician shares his perspective on critical cardiology care: improved communication technologies can save time and lives. Learn how now.
Learn how leading New York hospitals are critically thinking about, and planning for, I-STOP's mandatory introduction of EPCS processes.
Latest Version of Imprivata OneSign Improves Scalability and Expands Market-Leading Support for Desktop Virtualization Platforms and Thin/Zero Clients Lexington, Mass.—December 2, 2014—Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today introduced Imprivata OneSign® 5.0, the newest version of the company’s flagship authentication and access management solution.
This video highlights the benefits of electronic prescribing of controlled substances (EPCS) and provides an overview of the DEA regulatory requirements for EPCS.
Electronic prescribing of controlled substances (EPCS) has many benefits for prescribers, patients, IT, and pharmacy and hospital administration. But the DEA requirements for EPCS introduce complexities that need to be considered when developing a project plan.
Methodist Health System (Omaha, Neb.) leverages fingerprint biometric authentication from Imprivata to enable e-Prescribing of controlled substances to improve patient satisfaction, eliminate dual-prescribing workflows and address drug diversion.